These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17227802)

  • 21. Alendronate in the prevention of bone loss after a fracture of the lower leg.
    van der Poest Clement E; van Engeland M; Adèr H; Roos JC; Patka P; Lips P
    J Bone Miner Res; 2002 Dec; 17(12):2247-55. PubMed ID: 12469919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
    Shapiro J; Smith B; Beck T; Ballard P; Dapthary M; BrintzenhofeSzoc K; Caminis J
    Calcif Tissue Int; 2007 May; 80(5):316-22. PubMed ID: 17417700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of bone loss after withdrawal of tamoxifen.
    Cohen A; Fleischer JB; Johnson MK; Brown IN; Joe AK; Hershman DL; McMahon DJ; Silverberg SJ
    Endocr Pract; 2008 Mar; 14(2):162-7. PubMed ID: 18308653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Ward LM; Rauch F; Whyte MP; D'Astous J; Gates PE; Grogan D; Lester EL; McCall RE; Pressly TA; Sanders JO; Smith PA; Steiner RD; Sullivan E; Tyerman G; Smith-Wright DL; Verbruggen N; Heyden N; Lombardi A; Glorieux FH
    J Clin Endocrinol Metab; 2011 Feb; 96(2):355-64. PubMed ID: 21106710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alendronate for the treatment of osteoporosis in men.
    Orwoll E; Ettinger M; Weiss S; Miller P; Kendler D; Graham J; Adami S; Weber K; Lorenc R; Pietschmann P; Vandormael K; Lombardi A
    N Engl J Med; 2000 Aug; 343(9):604-10. PubMed ID: 10979796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone density around endosseous implants in patients taking alendronate: a pilot study.
    Griffiths GR
    Int J Periodontics Restorative Dent; 2012 Jun; 32(3):e101-8. PubMed ID: 22408779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
    Rudge S; Hailwood S; Horne A; Lucas J; Wu F; Cundy T
    Rheumatology (Oxford); 2005 Jun; 44(6):813-8. PubMed ID: 15695300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
    J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
    Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial.
    Golden NH; Iglesias EA; Jacobson MS; Carey D; Meyer W; Schebendach J; Hertz S; Shenker IR
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3179-85. PubMed ID: 15784715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
    Bettembuk P; Balogh A
    Orv Hetil; 1999 Dec; 140(50):2799-803. PubMed ID: 10647267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.